Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
131
resultados
Última actualización
11/06/2026 [06:55:00]
Resumen de: US2025049355A1
Certain aspects of the present disclosure provide a monitoring system comprising a continuous analyte sensor configured to penetrate a skin of a patient and generate a sensor current indicative of analyte levels of the patient, and a sensor electronics module coupled to the continuous analyte sensor. The sensor electronics module comprises an analog to digital converter configured to receive the sensor and convert the sensor current generated by the continuous analyte sensor into digital signals, one or more processors configured to convert the digital signals to a set of analyte measurements indicative of the analyte levels of the patient, and a Bluetooth antenna configured to transmit the set of analyte measurements wirelessly to a wireless communications device using Bluetooth or BLE communications protocols.
Resumen de: WO2025029671A1
Disclosed herein are methods of treating a subject having diabetes with a population of cells expressing ISL1 and one or more immunosuppressive reagents, such as an anti-thymocyte globulin binding moiety.
Resumen de: EP4756833A1
The invention discloses a diabetes management system for use in a hospital, including: at least a wearable medical device, a plurality of receivers, a central server and a healthcare provider terminal, the receivers receive the data information transmitted by the medical device and upload it to the central server, and the healthcare provider communicates with the central server and displays or reviews the medical data information through the terminal, as any one of the multiple receivers can receive the data information transmitted by the medical device and upload it to the central server, as a result, the patient's range of motion in the hospital is no longer restricted, which improves the patient's experience and keeps the patient in a comfortable mood, while the healthcare provider is able to know the patient's blood glucose level and/or insulin infusion state in real time through the healthcare provider terminal and deal with the abnormalities in a timely manner, so that the patient's blood glucose level can be maintained at a stable level.
Resumen de: US20260151565A1
The exemplary embodiments provide an automated approach for adjusting the medicament delivery rate to the user when operating in an open loop manner (“open mode”). The approach relies upon an insulin delivery history to the user make adjustments to the medicament delivery rate in the open mode. In particular, the exemplary embodiments may look at the medicament delivery history while the medicament delivery device is operating in a closed loop manner (“closed mode”) to determine how to adjust the open mode medicament delivery rate. It is presumed that in closed mode, the control system of the medicament device has gained knowledge over time about how to control the medicament delivery rate to produce good treatment outcomes for the user. The exemplary embodiments leverage this knowledge to adjust the open mode medicament delivery rates. Medicament bolus deliveries in open mode may also be adjusted in like fashion.
Resumen de: WO2026116775A1
Disclosed is a blood glucose measurement device capable of improving blood glucose measurement accuracy by focusing rays of light for blood glucose measurement in the measurement area of an object. According to an embodiment of the present invention, the blood glucose measurement device comprises: a light source unit disposed to output a plurality of first light rays for measuring blood glucose in the measurement area of an object; an optical unit including one or more optical bodies disposed to emit a plurality of first light rays toward the measurement area of the object; and a light-receiving unit disposed to receive a plurality of second light rays output through an interaction between the plurality of first light rays and the object. The one or more optical bodies include: a plurality of lenses arranged to condense a plurality of first light rays on the first surface of one or more optical bodies facing the light source unit; a reflective surface arranged to reflect a plurality of first light rays condensed by the plurality of lenses on the second surface of one or more optical bodies; and a refractive surface arranged to refract a plurality of first light rays reflected at the reflective surface toward the measurement area of the object on the third surface of one or more optical bodies.
Resumen de: WO2026114787A1
A method (100) for adjusting a first biomarker measurement, comprising: receiving (120) a first biomarker measurement from a subject; contemporaneously receiving (130) a time-dependent biomarker measurement from the subject; comparing (140) the time-dependent biomarker measurement to a subject-determined baseline; determining (150), based on the comparison, a time-warp of a baseline first biomarker measurement; and adjusting (160) the baseline first biomarker measurement by the determined amount of the time-warp to generate an adjusted first biomarker measurement.
Resumen de: WO2026114687A1
A method for identifying a deviation of a first biomarker measurement, comprising: receiving a first biomarker measurement from a subject at a first timepoint; comparing the received first biomarker measurement to a subject-determined baseline of first biomarker measurements; determining, based on the comparison, that the first biomarker measurement is a deviation from the subject-determined baseline of first biomarker measurements; and reporting the determined deviation of the first biomarker measurement.
Resumen de: US20260151059A1
Analyte sensor apparatus, systems, and methods to reduce sensor drift. An analyte sensor apparatus (102) for detecting an analyte such as glucose in a target environment (10) such as a body tissue may include a plurality of electrodes and a controller. The plurality of electrodes may provide a plurality of electrode signals based on the target environment while disposed in the target environment. The controller may be operatively coupled to the plurality of electrodes and configured to receive the plurality of electrode signals. The controller may further be configured to adjust a voltage of at least one electrode of the plurality of electrodes based on a voltage profile to regenerate one or more electrodes of the plurality of electrodes while the at least one electrode is disposed in the target environment. This may allow to correct an electrode drift without removing the electrode from its target environment.
Resumen de: US20260151570A1
A method may include displaying at least three icons on a user interface of a mobile device, including a first icon associated with the at least three icons associated with a first carbohydrate level, a second icon associated with the at least three icons associated with a second carbohydrate level, and a third icon associated with the at least three icons associated with a third carbohydrate level. The method may also include receiving a user selection of one of the three icons through the user interface of the mobile device, and determining an insulin bolus level from the user selection. The method may also include communicating the insulin bolus level to an insulin delivery device.
Resumen de: US20260151056A1
0000 Techniques disclosed herein relate to calibrating glucose values. In some embodiments, the techniques may involve measuring one or more calibration values of an operating parameter of one or more monitor electrodes. The techniques may further involve determining one or more delta values using the one or more calibration values and one or more pre-calibration values, wherein the one or more delta values are indicative of a first reaction of a first chemistry stack of the one or more monitor electrodes. The techniques may further involve utilizing a relationship between a second reaction of a second chemistry stack disposed on one or more working electrodes and a first reaction of the first chemistry stack to translate the one or more delta values associated with the operating parameter of the one or more monitor electrodes to a change in an operating parameter of one or more working electrodes.
Resumen de: WO2025021960A1
The present invention relates to a biosensor for measuring the concentration of glucose and its use in glucose sensing. The biosensor of the present invention comprises a polymer comprising a boronic acid-based glucose-binding moiety, wherein said boronic acid-based glucose-binding moiety is immobilized in said polymer, and an inhibitor moiety, wherein said inhibitor moiety is immobilized in said polymer, and wherein said inhibitor moiety is capable of forming reversible crosslinks by binding to said boronic acid-based glucose-binding moiety. In the absence of glucose, the polymer is crosslinked by a bond formed between the boronic acid-based glucose-binding moiety and the inhibitor moiety. In the presence of glucose, the boronic acid-based glucose-binding moiety binds to glucose, whereby the bond between the boronic acid-based glucose-binding moiety and the inhibitor moiety is broken, which results in a change of volume of the polymer. The biosensor of the present invention is particularly useful for glucose monitoring performed on a subject under intensive care as well as in the situations wherein the glucose monitoring is performed on an unconscious subject.
Resumen de: WO2025021930A1
The present invention relates to a biosensor for measuring the concentration of glucose and its use in glucose sensing, wherein the biosensor comprising a polymer comprising the moiety of formula (I). The biosensor of the present invention is particularly useful for glucose monitoring performed on a subject under intensive care as well as in the situations wherein the glucose monitoring is performed on an unconscious subject.
Resumen de: WO2026112485A1
The present disclosure is directed to a bio-feedback sensor in combination with AI and ML that can be implemented to optimize neuromodulation parameters for the management of a medical condition such a type II diabetes. The bio-feedback obtained by the sensors is optimized by the ML tools to predict and recommend the upregulation or downregulating the neuroregulators to modulate treatment. The algorithms could also learn to sense a life-threating pathological state, or bio-chemical imbalance, and in the case of diabetes a life-threating low blood sugar level the system overrides to stimulate the target fibers that control organs to regulate blood glucose levels.
Resumen de: WO2026110048A1
The present invention provides an automated portable wireless diabetic foot risk profiler system. The system comprises portable devices include a first portable device (103) configured to perform neuropathy assessment by producing a vibration and tactile sensation and detecting the response of a patient, and a second portable device (104) configured to perform vascular assessment by measuring blood pressure and detecting pulse wave pattern of the patient. The central control panel (102) perform real-time data acquisition and processing of a data including response of a patient to said vibration and tactile sensation along with the blood pressure measurement and pulse wave patterns. The remote response button unit (105) is for getting response directly from the patient to capture the value of tactile and vibration sensation in real time. The remote server (101) is for remote synchronization of data and remote data management.
Resumen de: US20260144928A1
0000 Provided herein are systems and methods for delivering medication, such as insulin, that are user-friendly, environmentally-friendly, lower cost, discreet, less prone to errors, and/or that deliver precise, repeatable doses of medication, as well as accessories for applying and managing the same. In embodiments, the system includes a wearable insulin pump having a patch-style form factor for adhesion to a user's body surface.
Resumen de: WO2026109522A1
Apparatuses, systems, and techniques are described to integrate the operations of a computational platform with a third-party application. The computational platform can perform operations related to medical data and non-medical data. The medical data can be routed to services that comply with one or more first regulatory frameworks. The non-medical data can be routed to services that comply with one or more second regulatory frameworks. The medical data can be related to the treatment and care of diabetes.
Resumen de: WO2026107792A1
A blood glucose management system, comprising: in a first operation mode, a program module (101) identifies the signal intensity of a broadcast signal; when the signal intensity of the broadcast signal is not less than a preset signal intensity threshold, the program module (101) establishes a wireless communication connection with a measurement module (100) and/or an infusion module (102) that sends the broadcast signal; in a second operation mode, a device identifier of the measurement module (100) and/or the infusion module (102) is inputted so as to establish the wireless communication connection.
Resumen de: US20260144933A1
The disclosed embodiments are directed to methods for dynamically adjusting the total daily insulin requirements of a user during pregnancy, based on the gestational week. An initial estimate of the adjusted total daily insulin requirement may be calculated as a multiple of the pre-pregnancy total daily insulin requirement, based on an average scale factor from a population of pregnant women suffering from Type I diabetes mellitus. An automatic drug delivery device may adjust the initial estimate of the total daily insulin requirement based on blood glucose level readings from a continuous glucose monitor during the course of the pregnancy.
Resumen de: US20260144934A1
0000 A portable infusion pump can communicate with glucose monitor, such as a continuous glucose monitor (CGM), to receive continuous feedback relating to a user's blood glucose level during insulin or other medicament therapy and can automatically deliver insulin to a user when the CGM data indicates a need for additional insulin. Due to potential unreliability in the correlation of the CGM data to the user's actual blood glucose level, risk mitigation can be employed to limit the amount of extra insulin that can be delivered by the pump in response to the CGM data.
Resumen de: WO2026107790A1
Disclosed in the present invention is a blood glucose management system for establishing a wireless communication connection on the basis of signal strength. A signal strength threshold is preset in the blood glucose management system. During a period when a monitoring module and/or an infusion module is powered on and sends a broadcast signal, a program module searches for a nearby broadcast signal and identifies the signal strength of the broadcast signal. When the signal strength of the broadcast signal is not less than the preset signal strength threshold, the program module can establish a wireless communication connection with the monitoring module and/or the infusion module that sends the broadcast signal, without the need to input a device identifier of the monitoring module and/or the infusion module. Moreover, since the broadcast signal identified by the program module is sufficiently strong, it means that the program module is in proximity to the monitoring module and/or the infusion module that sends the broadcast signal, thereby ensuring the reliability of the program module establishing a wireless communication connection with a patient's own monitoring module and/or infusion module.
Resumen de: WO2026111961A1
Aspects of the present disclosure include methods for treating a subject having a metabolic disorder by neuromodulation. Methods according to certain embodiments include applying electrical stimulation to the spinal cord of a subject (e.g., a subject diagnosed as having or determined to have diabetes or prediabetes) in a manner sufficient to treat at least one symptom of the metabolic disorder in the subject. In some embodiments, neuromodulation is sufficient to treat one or more symptoms of diabetes or prediabetes such as fasting plasma glucose concentration, non-fasting plasma glucose concentration, elevated hbA1c, glucose tolerance and insulin secretion by the subject. Systems having one or more electrodes configured for applying electrical stimulation to the spinal cord of the subject suitable for practicing the subject methods are also described.
Resumen de: WO2026112174A1
Methods are provided for generating pancreatic endocrine cells from pluripotent stem cells (PSCs) using epigenetic modifiers. A fusion protein comprising catalytically inactivated Cas9 (dCas9) and an embryonic ectoderm development (EED)-binding domain (EBdCas9) is used with guide RNAs (gRNAs) to target regulatory regions of transcriptional regulators including EOMES, PDX1, and NGN3. Sequential targeting of PDX1 and NGN3 promoters with EBdCas9 removes repressive H3K27me3 marks, increases activating H3K27ac modifications, and accelerates differentiation into insulin-producing β-cells. The methods significantly increase β-cell yields (~4-6 fold), reduce non-pancreatic lineage contaminants (CDX2+, SOX2+, enteroendocrine cells), enhance mitochondrial function, and produce glucose-responsive cells with superior functional maturation in vivo. The epigenetic interventions enforce pancreatic developmental fates while activating NGN3-dependent transcriptional programs necessary for endocrine cell differentiation, insulin secretion, and metabolic maturation. Cells and compositions produced by these methods are also provided.
Resumen de: EP4749952A2
0001 The present invention relates generally to systems and methods for processing, transmitting, and displaying data received from continuous analyte sensor 10, such as a glucose sensor. In some embodiments, the continuous analyte sensor system 8 comprises a sensor electronics module 12 that includes power saving features. One feature includes a low power measurement circuit that can be switched between a measurement mode and a low power mode, in which charging circuitry continues to apply power to electrodes of a sensor during the low power mode. In addition, the sensor electronics module can be switched between in a low power storage mode higher power operational mode via a switch. The switch can include a reed switch or optical switch, for example. A validation routine can also be implemented to ensure an interrupt signal sent from the switch is valid. The continuous analyte sensor 10 can be physically connected to a sensor electronics module 12, which is in direct wireless communication with a plurality of different display devices 14, 16, 18, and/or 20.
Resumen de: EP4748379A1
0001 A use of uridine diphosphate glucose (UDPG) in treatment of abnormal liver glucolipid metabolism. Specifically, a use of UDPG or a pharmaceutical composition comprising same in the preparation of a drug for preventing and/or treating abnormal liver glucolipid metabolism, wherein the abnormal liver glucolipid metabolism is preferably nonalcoholic fatty liver disease, dyslipidemia and related cardiovascular diseases. Treatment using UDPG can reduce lipid synthesis and lipid synthesis related gene expression in the liver.
Nº publicación: EP4749425A2 27/05/2026
Solicitante:
DEXCOM INC [US]
Dexcom, Inc.
Resumen de: EP4749425A2
0001 A system, a method, and a computer program product for providing wearable continuous blood glucose monitoring. In some embodiments, there is provided a method that includes receiving, at a smartwatch, an alert representative of a glucose state of a host-patient coupled to a glucose sensor; detecting, at the smartwatch, a predetermined action indicative of a request to generate a glance view providing an indication of the glucose state of the host-patient; and presenting, at the smartwatch and in response to the detecting, the glance view providing the indication of the glucose state of the host-patient.
BOPI
Sede Electrónica
